US equities
|
NVDA
$181.60
▼-9.26%
MU
$656.39
▼-17.46%
AMD
$404.40
▼-17.26%
TSLA
$343.69
▼-10.77%
AAPL
$344.17
▼-1.53%
SNDK
$806.43
▼-22.26%
MSFT
$535.93
▼-3.58%
AMZN
$260.21
▼-2.19%
NVDA
$181.60
▼-9.26%
MU
$656.39
▼-17.46%
AMD
$404.40
▼-17.26%
TSLA
$343.69
▼-10.77%
AAPL
$344.17
▼-1.53%
SNDK
$806.43
▼-22.26%
MSFT
$535.93
▼-3.58%
AMZN
$260.21
▼-2.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Collegium Pharmaceutical, Inc. - Common Stock
(NQ:
COLL
)
25.16
+1.49 (+6.29%)
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Collegium Pharmaceutical, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Collegium (COLL) Q3 2026 Earnings Call Transcript
↗
Today 15:13 EST
Jornay PM growth outpaced a steep pain-segment drop this quarter.
Via
The Motley Fool
Topics
Earnings
Collegium Pharmaceutical Q3 Earnings Call Highlights
↗
Today 10:14 EST
Collegium Pharmaceutical (NASDAQ:COLL) reported record third-quarter 2026 revenue as growth in its attention-deficit/hyperactivity disorder portfolio helped offset declining sales of pain medicines....
Via
MarketBeat
Topics
Earnings
Collegium Pharmaceutical (NASDAQ:COLL) Posts Mixed Q3 as EPS Beats, Revenue Misses, and Guidance Holds
↗
Today 8:34 EST
Via
Chartmill
Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars
Today 8:33 EST
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) met Wall Street’s revenue expectations in Q3 2026, with revenue up 3.3% year on year to $216.3 ...
Via
StockStory
Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance
↗
August 06, 2026
Via
Chartmill
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
Today 7:30 EST
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (COLL) Q3 earnings: what to expect
November 03, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before the bell. Here’s what investors should...
Via
StockStory
Topics
Artificial Intelligence
1 of Wall Street’s favorite stocks with promising prospects and 2 we turn down
October 30, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via
StockStory
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
October 29, 2026
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks
October 25, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Collegium Pharmaceutical (NAS...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
October 22, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
October 21, 2026
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release...
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
October 06, 2026
New resource hub builds on Collegium’s growing ADHD portfolio and commitment to supporting people and families beyond the clinical setting
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
3 Healthcare Stocks That Concern Us
September 30, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Via
StockStory
3 Value Stocks That Fall Short
September 28, 2026
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via
StockStory
1 Oversold Stock Ready to Bounce Back and 2 We Find Risky
September 22, 2026
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether...
Via
StockStory
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
September 21, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
Topics
Stocks
Collegium to Participate in Upcoming Investor Conferences
September 08, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Jornay PM revenue surged 41% as Collegium integrated Azstarys and expanded its sales force.
Via
The Motley Fool
Topics
Earnings
Collegium Announces $50 Million Accelerated Share Repurchase Program
August 13, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
August 13, 2026
Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Man...
Via
StockStory
Topics
Earnings
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
August 07, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ...
Via
StockStory
Collegium Pharmaceutical Q2 Earnings Call Highlights
↗
August 06, 2026
Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower...
Via
MarketBeat
Topics
Earnings
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops
August 06, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ...
Via
StockStory
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
August 06, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
August 04, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to look for. Collegium ...
Via
StockStory
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks
July 23, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
July 20, 2026
New headquarters reflects Collegium's long-term vision and commitment to Massachusetts
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
1 Healthcare Stock with Competitive Advantages and 2 We Question
July 16, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial ...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
